drugset
drugset / Trial / NCT05113953

A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder

NCT05113953 ↗

Phase 2 Completed 147 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to assess the efficacy of 2 doses of centanafadine sustained-release (SR) (200 milligrams \[mg\] and 400 mg total daily dose \[TDD\]) compared with placebo in adults with moderate to severe binge eating disorder (BED).

Timeline

Start
2021-12-22
Primary completion
2022-08-19
Completion
2022-08-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Centanafadine Small molecule 200 mg Oral
Subject Centanafadine Small molecule 400 mg Oral

Indications

binge eating disorder